|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:access
|
patient assistance program
|
|
gptkbp:approves
|
gptkb:2020
gptkb:FDA
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:chemical_formula
|
C20 H24 N4 O3 S
|
|
gptkbp:clinical_trial
|
gptkb:Rising
Phase 3
FIREFISH
SUNFISH
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:community_support
|
SMA advocacy groups
|
|
gptkbp:contraindication
|
hypersensitivity to risdiplam
|
|
gptkbp:country_of_origin
|
gptkb:Switzerland
|
|
gptkbp:developed_by
|
gptkb:Roche
|
|
gptkbp:dosage_form
|
suspension
|
|
gptkbp:drug_interactions
|
none known
|
|
gptkbp:effective_date
|
August 7, 2020
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:feedback
|
generally positive
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
gptkb:liquid
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Evrysdi
|
|
gptkbp:indication
|
treatment of SMA in patients 2 months and older
|
|
gptkbp:ingredients
|
gptkb:risdiplam
|
|
gptkbp:invention
|
patented
|
|
gptkbp:label
|
prescription only
|
|
gptkbp:launch_date
|
gptkb:2020
|
|
gptkbp:lifespan
|
approximately 30 hours
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:marketed_as
|
gptkb:Evrysdi
|
|
gptkbp:mechanism_of_action
|
increases SMN protein levels
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_education
|
provided by healthcare professionals
|
|
gptkbp:patient_population
|
infants and children
|
|
gptkbp:pharmacokinetics
|
studied in healthy volunteers
SMN2 gene modulation
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
included in SMA treatment guidelines
|
|
gptkbp:regulatory_compliance
|
internationally recognized
|
|
gptkbp:reimbursement
|
insurance coverage available
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:research_focus
|
SMA treatment advancements
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
monitor liver function
|
|
gptkbp:service_frequency
|
once daily
|
|
gptkbp:side_effect
|
fatigue
nausea
fever
diarrhea
rash
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:supply_chain
|
global
|
|
gptkbp:target_audience
|
children and adults with SMA
|
|
gptkbp:treatment
|
improved motor function
|
|
gptkbp:used_for
|
gptkb:muscular_dystrophy
|
|
gptkbp:bfsParent
|
gptkb:risdiplam
|
|
gptkbp:bfsLayer
|
6
|